Search Results

You are looking at 21 - 30 of 40 items for :

  • "accelerated phase" x
  • Refine by Access: All x
Clear All
Full access

Allogeneic Stem Cell Transplantation for Philadelphia Chromosome–Positive Acute Myeloid Leukemia

Vijaya Raj Bhatt, Mojtaba Akhtari, R. Gregory Bociek, Jennifer N. Sanmann, Ji Yuan, Bhavana J. Dave, Warren G. Sanger, Anne Kessinger, and James O. Armitage

distinguish between the entities. 4 Clinical characteristics might also be helpful in making the distinction, including no history of CML or myeloproliferative disorder, no evidence of chronic or accelerated phases of CML after induction therapy, and no

Full access

Beyond BCR::ABL1—The Role of Genomic Analyses in the Management of CML

Susan Branford, Adelina Fernandes, NurHezrin Shahrin, Muneeza Maqsood, Naranie Shanmuganathan, and Carol Wadham

testing for patients with CML. 1 The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for CML indicate that myeloid mutation panel testing could be considered for patients who present in accelerated phase or BP. 1 At resistance, myeloid

Full access

What Happens When Imatinib Goes Generic?

Jean McDougall, Scott D. Ramsey, and Jerald Radich

myeloid leukemia . N Engl J Med 2003 ; 348 : 994 – 1004 . 15. le Coutre PD Giles FJ Hochhaus A . Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow

Full access

Controversies Regarding Use of Myeloid Growth Factors in Leukemia

Jacqueline N. Poston and Pamela S. Becker

/4 myelosuppression for patients with CML on omacetaxine, and the need to use G-CSF in 25% of patients with chronic-phase and 10% of patients with accelerated-phase disease. Studies initially focused on the use of growth factor to prevent neutropenia, and later to see

Full access

New Agents in Chronic Myelogenous Leukemia

Jorge Cortes and Francis Giles

transferase inhibitor (FTI), in patients with chronic myeloid leukemia (CML) in chronic or accelerated phase resistant or refractory to imatinib (Abstr #614) . Blood 2002 ; 100 : 164a . 44 Forkner CE Scott TF . Arsenic as a therapeutic agent in

Full access

Current Issues in Chronic Myeloid Leukemia: Monitoring, Resistance, and Functional Cure

Jorge Cortes, John M. Goldman, and Timothy Hughes

) and a higher rate of progression than those with better molecular responses, whereas patients who achieved MMR ( BCR-ABL transcript levels ≤0.1% on the IS) experienced durable responses, no progression to accelerated-phase (AP) or blast-phase (BP

Full access

NCCN Task Force Report: Molecular Markers in Leukemias and Lymphomas

Jerald P. Radich, Andrew D. Zelenetz, Wing C. Chan, Carlo M. Croce, Myron S. Czuczman, Harry P. Erba, Sandra J. Horning, Jane Houldsworth, B. Douglas Smith, David S. Snyder, Hema M. Sundar, Meir Wetzler, and Jane N. Winter

– 3213 . 69 Guilhot F Apperley J Kim DW . Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase . Blood . 2007 ; 109 : 4143 – 4150

Full access

Maintenance Therapy With Tyrosine Kinase Inhibitors After Transplant in Patients With Chronic Myeloid Leukemia

Merav Bar and Jerald Radich

leukemia (CML). Survival rates were greater than 80% for chronic phase (CP), 40% for accelerated phase (AP), and 20% for blast crisis phase (BP) CML. In most major transplant settings, survival rates for matched related and unrelated transplants are similar

Full access

Long-Term Patterns of Oral Anticancer Agent Adoption, Duration, and Switching in Patients With CML

Matthew P. Banegas, Donna R. Rivera, Maureen C. O’Keeffe-Rosetti, Nikki M. Carroll, Pamala A. Pawloski, David C. Tabano, Mara M. Epstein, Kai Yeung, Mark C. Hornbrook, Christine Lu, and Debra P. Ritzwoller

G , . Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy . Leukemia 2010 ; 24 : 1299 – 1301 . 10.1038/leu.2010.110 20520639 27. Ibrahim AR , Paliompeis C , Bua

Full access

Myeloid/Lymphoid Neoplasms with Eosinophilia and TK Fusion Genes, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology

Aaron T. Gerds, Jason Gotlib, Prithviraj Bose, Michael W. Deininger, Andrew Dunbar, Amro Elshoury, Tracy I. George, Ivana Gojo, Krishna Gundabolu, Elizabeth Hexner, Gabriela Hobbs, Tania Jain, Catriona Jamieson, Andrew T. Kuykendall, Brandon McMahon, Sanjay R. Mohan, Vivian Oehler, Stephen Oh, Animesh Pardanani, Nikolai Podoltsev, Erik Ranheim, Lindsay Rein, Rachel Salit, David S. Snyder, Brady L. Stein, Moshe Talpaz, Swapna Thota, Pankit Vachhani, Martha Wadleigh, Katherine Walsh, Dawn C. Ward, Mary Anne Bergman, and Hema Sundar

typical aggregates found in SM. 16 There is no current definition for accelerated phase disease; however, the presence of 10% to 19% blasts in the bone marrow or peripheral blood has been used to define accelerated phase similar to myeloid neoplasms such